Celularity Inc.
CELUDrugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
CELU Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | FQ end Jun/2026 | Call: tbd
PDA-002
Diabetic Nephropathies
CYNK-001
Coronavirus
Human Placenta-Derived Cells PDA001 Intravenous Infusion
Crohn's Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
PDA-002 | Phase 2 | Diabetic Nephropathies | - | - |
CYNK-001 | Phase 2 | Coronavirus | - | - |
Human Placenta-Derived Cells PDA001 Intravenous Infusion | Phase 2 | Crohn's Disease | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Celularity Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Celularity Inc.'s (CELU) pipeline across Phase 2. Its lead program is PDA-002 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Celularity Inc.'s next FDA catalyst?→
Celularity Inc.'s (CELU) next tracked catalyst is a Earnings expected October 2, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CELU biotech catalysts?→
Add CELU to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Celularity Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.